Key facts
- This page summarizes Christopher A. Toth's Form 4 filing for BAXTER INTERNATIONAL INC (BAX).
- 1 reported transaction and 0 derivative rows are listed below.
- Accepted by SEC: 05 Jun 2023, 16:03.
Christopher A. Toth - 01 Jun 2023 Form 4 Insider Report for BAXTER INTERNATIONAL INC (BAX)
- Reporting relationship
- EVP, Group Pres, Kidney Care
- Issuer ticker
- BAX
- Reported as of
- 01 Jun 2023
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 05 Jun 2023, 16:03:25 UTC
- Next SEC filing
- 08 Mar 2024
- Source filing
- View source filing
- Reporting owner signature
- /s/ Matthew Rice, as attorney in-fact for Christopher A. Toth
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
Christopher A. Toth filed Form 4 for BAXTER INTERNATIONAL INC (BAX) on 05 Jun 2023.
Change
- No earlier filing in this sequence is available for direct comparison.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
BAX
transaction
Common Stock, $1 par value
Award
- Transaction value
- $0
- Shares
- +106,358
- Change %
- Price
- $0.000000
- Shares after
- 106,358
- Date
- 01 Jun 2023
- Ownership
- Direct
- Footnotes
- F1
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 1 footnote
Footnote F1
Mr. Toth received a grant of restricted stock units (RSUs)in connection with his appointment as EVP and Group President, Kidney Care. The RSUs are scheduled to vest in three equal annual installments beginning on June 3, 2024, the first anniversary of the grant date, subject to the terms and conditions set forth in the Baxter International Inc. 2021 Equity Plan. However, this award grant will vest in full if (i) by December 31, 2024, the proposed separation of the Kidney Care business (comprised of the Renal Care and Acute Therapies businesses) as a separately traded company (the "Business Transaction") does not occur; or (ii) in connection with the consummation of the Business Transaction, Mr. Toth is not appointed as Chief Executive Officer of the new company, Kidney Co.